Key statistics
On Monday, NervGen Pharma Corp (9UA:STU) closed at 3.50, 118.75% above the 52 week low of 1.60 set on Aug 21, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 3.48 |
|---|---|
| High | 3.54 |
| Low | 3.42 |
| Bid | 3.50 |
| Offer | 3.62 |
| Previous close | 3.52 |
| Average volume | 0.00 |
|---|---|
| Shares outstanding | 80.39m |
| Free float | 63.40m |
| P/E (TTM) | -- |
| Market cap | 461.43m CAD |
| EPS (TTM) | -0.3622 CAD |
Data delayed at least 15 minutes, as of Feb 16 2026.
More ▼
Announcements
- NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams
- NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium
- NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company’s Growth and Execution of Its Mission in Spinal Cord Injury
- NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing
- NervGen Pharma Begins Trading on Nasdaq Today
- NervGen Pharma Reports Positive Topline Data from the Chronic Cohort of its Phase 1b/2a Clinical Trial Evaluating NVG-291 in Spinal Cord Injury
More ▼
